



**Department of Vermont Health Access
Pharmacy Benefits Management Program
*DUR Board Meeting Agenda***

May 15, 2012 6:30 – 9:00 p.m.

- 1. Executive Session** **6:30 - 7:00**
 - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements (as provided by 33 VSA § 1998(f)(2))

- 2. Introductions and Approval of DUR Board Minutes** **7:00 - 7:05**

(Public Comment Prior to Board Action)

- 3. DVHA Pharmacy Administration Updates** **7:05 - 7:15**
 - Legislative Update

- 4. Medical Director Update** **7:15 - 7:20**
 - Clinical Programs Update
 - Prescriber Comments

- 5. Follow-up Items from Previous Meetings** **7:20 - 7:35**
 - Suboxone[®] Film Provider Exemption

- 6. RetroDUR/DUR** **7:35 – 7:55**
 - Narcotic Analgesics – Long/Short Acting Combination
 - Xifaxan[®] (rifaximin)

- 7. Clinical Update: Drug Reviews** **7:55 – 8:00**

(Public comment prior to Board action)

Full New Drug Reviews

 - Solesta[®] Gel Prefilled Syringe for Submucosal Injection

- 8. Therapeutic Drug Classes – Periodic Review** **8:00 – 8:30**

(Public comment prior to Board action)

Class review documents available on DVHA web site 5/15/2012 @ 12 Noon

 - Atypical Antipsychotics (with particular emphasis on pediatric use)

- 9. New Managed Therapeutic Drug Classes** **8:30 – 8:40**

(Public comment prior to Board action)

 - Rifamycins (to replace Hepatic Encephalopathy class)

- 10. Review of Newly-Developed/Revised Clinical Coverage Criteria and/or Preferred Products** **8:40 – 8:55**

(Public comment prior to Board action)

 - Anti-hyperkinesia and Anti-Narcolepsy: ADHD (quantity limits)
 - Multiple Sclerosis Medications (new information Gilenya[®] and Tysabri[®]; Ampyra[®])
 - Nutritional Products

11. General Announcements

8:55– 9:00

Selected FDA Safety Alerts

- Aliskiren-Market withdrawal of Valtorna®
- Tysabri® - Drug Safety Communication – Update of Risk Factors for PML

12. Adjourn

9:00